Breaking News

Emergent BioSolutions Signs $53 Million BARDA Contract

Represents a modification of the current contract with the gov’t agency for the manufacture of botulism antitoxin

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Emergent BioSolutions has signed a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) to manufacture and store bulk drug substance for its botulism antitoxin, BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)], valued at approximately $53 million with a five-year period of performance. This modification to the contract will enable future filling and deliveries of final drug product to the Strategic National Stockpile (SNS...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters